{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:53:00Z","timestamp":1794048780109,"version":"4.8.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.tjpad.2026.100605","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:13:30Z","timestamp":1779887610000},"page":"100605","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of donanemab in the European eligible population: TRAILBLAZER-ALZ 2 post-hoc analyses"],"prefix":"10.1016","volume":"13","author":[{"given":"Frank","family":"Jessen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5482-6065","authenticated-orcid":false,"given":"Grazia","family":"Dell\u2019Agnello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7655-7129","authenticated-orcid":false,"given":"Christophe","family":"Sapin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Dichter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1400-4427","authenticated-orcid":false,"given":"Erin","family":"Doty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4059-2891","authenticated-orcid":false,"given":"St\u00e9phane","family":"Epelbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia D.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2889-235X","authenticated-orcid":false,"given":"Paula M.","family":"Hauck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3728-7987","authenticated-orcid":false,"given":"Rashna","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2009-0493","authenticated-orcid":false,"given":"Dawn A.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5090-7886","authenticated-orcid":false,"given":"John R.","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3121-4979","authenticated-orcid":false,"given":"Federica","family":"Agosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjpad.2026.100605_bib0001","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's Disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjpad.2026.100605_bib0002","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.tjpad.2026.100605_bib0004","unstructured":"European Medicines Agency. Kisunla - assessment report 2025. Accessed January 12, 2026. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/kisunla-epar-public-assessment-report_en.pdf."},{"key":"10.1016\/j.tjpad.2026.100605_bib0006","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3174\/ajnr.A8469","article-title":"Alzheimer Disease Anti-Amyloid immunotherapies: imaging recommendations and practice considerations for monitoring of amyloid-related imaging abnormalities","volume":"46","author":"Cogswell","year":"2025","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.tjpad.2026.100605_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100446","article-title":"Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension","volume":"13","author":"Zimmer","year":"2026","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2026.100605_bib0008","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1080\/10543406.2013.834911","article-title":"Analysis of longitudinal trials with protocol deviation: a framework for relevant, accessible assumptions, and inference via multiple imputation","volume":"23","author":"Carpenter","year":"2013","journal-title":"J Biopharm Stat"},{"key":"10.1016\/j.tjpad.2026.100605_bib0009","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/pst.1536","article-title":"A structured approach to choosing estimands and estimators in longitudinal clinical trials","volume":"11","author":"Mallinckrodt","year":"2012","journal-title":"Pharm Stat"},{"key":"10.1016\/j.tjpad.2026.100605_bib0010","article-title":"Assessing clinical meaningfulness in clinical trials for Alzheimer's disease: a U.S. regulatory perspective","volume":"11","author":"Buracchio","year":"2025","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.tjpad.2026.100605_bib0011","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13195-020-00659-6","article-title":"Assessing what matters most to patients with or at risk for Alzheimer's and care partners: a qualitative study evaluating symptoms, impacts, and outcomes","volume":"12","author":"DiBenedetti","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.tjpad.2026.100605_bib0012","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40120-023-00445-0","article-title":"Assessing what matters to people affected by Alzheimer's disease: a quantitative analysis","volume":"12","author":"Hauber","year":"2023","journal-title":"Neurol Ther"},{"key":"10.1016\/j.tjpad.2026.100605_bib0013","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.14283\/jpad.2024.153","article-title":"Progress in the treatment of Alzheimer's Disease is needed - position statement of European Alzheimer's Disease Consortium (EADC) investigators","volume":"11","author":"Jessen","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2026.100605_bib0014","article-title":"Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction","volume":"21","author":"Wang","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2026.100605_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100266","article-title":"The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema\/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6","volume":"12","author":"Wang","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2026.100605_bib0016","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10928-024-09959-y","article-title":"Quantifying natural amyloid plaque accumulation in the continuum of Alzheimer's disease using ADNI","volume":"52","author":"Elhefnawy","year":"2025","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.tjpad.2026.100605_bib0017","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000011524","article-title":"Alzheimer's Disease neuroimaging I. Temporal dynamics of beta-amyloid accumulation in aging and Alzheimer Disease","volume":"96","author":"Jagust","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.tjpad.2026.100605_bib0018","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s40120-021-00272-1","article-title":"Estimating progression rates across the spectrum of Alzheimer's Disease for amyloid-positive individuals using National Alzheimer's Coordinating Center data","volume":"10","author":"Potashman","year":"2021","journal-title":"Neurol Ther"},{"key":"10.1016\/j.tjpad.2026.100605_bib0019","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70624","article-title":"Rates of clinical progression according to biological Alzheimer's disease stages","volume":"21","author":"Trudel","year":"2025","journal-title":"Alzheimers Dement"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726001305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726001305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T15:55:23Z","timestamp":1789487723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580726001305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2274580726001305"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100605","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of donanemab in the European eligible population: TRAILBLAZER-ALZ 2 post-hoc analyses","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100605","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Eli Lilly and Company. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100605"}}